A Randomized, 4-sequence, Cross-over, Double-blind, Dose Response Study of 0.4, 0.6 and 0.9 U/kg Insulin Glargine U300 Compared to 0.4 U/kg Lantus U100 in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique.

Trial Profile

A Randomized, 4-sequence, Cross-over, Double-blind, Dose Response Study of 0.4, 0.6 and 0.9 U/kg Insulin Glargine U300 Compared to 0.4 U/kg Lantus U100 in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 18 Jun 2013 Results presented at American Diabetes Association (ADA) 73rd Scientific Sessions, according to a Sanofi media release.
    • 13 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top